In the former, two distinct entities benefit from specific target therapies, namely MDS with low blasts and isolated 5q deletion (MDS-5q) and MDS with low blasts and SF3B1 mutation (MDS-SF3B1, formerly MDS-RS). The gene discussed is SF3B1; the disease is X-linked retinoschisis.